熱門資訊> 正文
礼来下一代糖尿病药物Mazdutide在3期试验中达到主要目标
2024-05-10 00:40
- A phase 3 trial in China of Eli Lilly's (NYSE:LLY) glucagon-like peptide-1 receptor (GLP-1) and glucagon receptor (GCGR) dual agonist mazdutide met its primary endpoint in a type 2 diabetes trial.
- Data indicated that mazdutide bested Lilly's Trulicity dulaglutide in terms of glycemic control. Also, those on mazdutide demonstrated weight loss, as well as improvements in blood lipid levels, blood pressure, serum uric acid, and liver enzymes.
- After 28 weeks of treatment, mazdutide 4 mg and 6 mg showed non-inferiority to dulaglutide 1.5 mg in improvement in HbA1c level from baseline. A superiority test indicated both doses of mazdutide were superior to dulaglutide.
- The results were released by Innovent Biologics (OTCPK:IVBIY), which has exclusive development and licensing rights for the candidate in China.
- Results from another Innovent (OTCPK:IVBXF) phase 3 study on mazdutide is slated to release mid-year followed by submission of a New Drug Application to China's Center for Drug Evaluation of the National Medical Products Administration.
More on Eli Lilly
- Eli Lilly: Great Time To Divest Before It Potentially Crashes
- Eli Lilly Remains Expensive Here - Minimal Margin Of Safety
- Eli Lilly: Don't Overpay For Miracle Drugs
- Eli Lilly Alzheimer’s therapy set for June FDA AdCom meeting
- Pharma R&D productivity seen improving for the first time in years - Deloitte
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
